CCAR-039 is under clinical development by Cellular Biomedicine Group and currently in Phase I for Primary Mediastinal B-Cell Lymphoma. According to GlobalData, Phase I drugs for Primary Mediastinal B-Cell Lymphoma have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how CCAR-039’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

CCAR-039 overview

CCAR-039 is under development for the treatment of non-Hodgkin's lymphoma (NHL), mantle cell lymphoma, diffuse large B-cell lymphoma and follicular lymphoma. It was under development for the treatment of acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL) and relapsed or refractory B-cell non-Hodgkin lymphoma. It is administered as an infusion. The immunotherapy constitutes bispecific chimeric antigen receptor (CAR) T cells. It acts by targeting CD19 and CD20 expressing cancer cells. The drug candidate is developed based on CAR-T platform, built on lenti-virial vector and second-generation CAR design,

Cellular Biomedicine Group overview

Cellular Biomedicine Group (CBMG) is a clinical stage biopharmaceutical firm that develops biomedicine, immunotherapy products for cancer and stem cell therapies to address patient specific medical conditions. The firm’s products comprise clinical treatment protocols for the treatment of knee osteoarthritis, cancer, asthma and chronic obstructive pulmonary diseases. It offers treatment protocol services such as orthopaedic diseases including osteoarthritis and tissue damage; and other indications. CBMG utilizes proprietary cell based technologies to produce raw material, manufacture cells, and conduct cell banking and distribution. The firm has operations in Hong Kong, China and the US. CBMG is headquartered in Cupertino, California, the US.

For a complete picture of CCAR-039’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.